| __timestamp | Intra-Cellular Therapies, Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 1643000000 |
| Thursday, January 1, 2015 | 18187286 | 1532000000 |
| Friday, January 1, 2016 | 24758063 | 1364000000 |
| Sunday, January 1, 2017 | 23666957 | 1334000000 |
| Monday, January 1, 2018 | 30099855 | 1484000000 |
| Tuesday, January 1, 2019 | 64947625 | 1638000000 |
| Wednesday, January 1, 2020 | 186363444 | 1726000000 |
| Friday, January 1, 2021 | 272611040 | 2001000000 |
| Saturday, January 1, 2022 | 358782000 | 2009000000 |
| Sunday, January 1, 2023 | 409864000 | 2151000000 |
| Monday, January 1, 2024 | 2318000000 |
Unlocking the unknown
In the ever-evolving landscape of the pharmaceutical industry, effective cost management is crucial. Over the past decade, Zoetis Inc. and Intra-Cellular Therapies, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Zoetis Inc. maintained a relatively stable SG&A expense, averaging around $1.7 billion annually, with a notable increase of 30% by 2023. In contrast, Intra-Cellular Therapies, Inc. experienced a dramatic rise, with expenses surging nearly 40 times from 2014 to 2023, reflecting their aggressive growth and expansion strategies. This divergence highlights the different paths companies can take in balancing growth with operational efficiency. As the industry continues to face challenges and opportunities, understanding these financial dynamics is key for investors and stakeholders alike.
Novo Nordisk A/S and Zoetis Inc.: SG&A Spending Patterns Compared
Johnson & Johnson vs Zoetis Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Zoetis Inc. vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Zoetis Inc. and Galapagos NV
Breaking Down SG&A Expenses: Zoetis Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Genmab A/S and Intra-Cellular Therapies, Inc.
Neurocrine Biosciences, Inc. or Intra-Cellular Therapies, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Blueprint Medicines Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Veracyte, Inc.
Intra-Cellular Therapies, Inc. and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Mesoblast Limited